A phase I/II, open-label, randomised study of nintedanib plus mFOLFOX6 versus bevacizumab plus mFOLFOX6 in first-line metastatic colorectal cancer patients

Annals of Oncology

Volumn 26, Issue 10, 2015, Pages 2085-2091

  Van Cutsem, Eric ^a   Prenen, H ^a   D'Haens, G ^b,c   Bennouna, J ^d   Carrato, A ^e   Ducreux, M ^f,g   Bouche O ^h   Sobrero, A ⁱ   Latini, L ^j   Staines, H ^k,o   Oum'Hamed, Z ^k   Dressler, H ^l   Studeny, M ^m   Capdevila, J ⁿ  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c IMELDA HOSPITAL   (Belgium)

^d CENTRE RENÉ GAUDUCHEAU   (France)

^e HOSPITAL RAMÓN Y CAJAL   (Spain)

^f INSTITUT GUSTAVE ROUSSY   (France)

^g UNIVERSITÉ PARIS SACLAY   (France)

^h REIMS UNIVERSITY HOSPITAL   (France)

ⁱ UNIVERSITY OF GENOA   (Italy)

^j Nuclear Medicine Unit   (Italy)

^k BOEHRINGER INGELHEIM   (France)

^l BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^m BOEHRINGER INGELHEIM RCV GMBH AND CO KG   (Austria)

ⁿ VALL D HEBRON UNIVERSITY HOSPITAL   (Spain)

^o NOVARTIS PHARMA AG   (Switzerland)

more..

Author keywords

Angiogenesis; CRC; FOLFOX; Nintedanib; VEGF

Indexed keywords

BEVACIZUMAB; FLUOROURACIL; FOLINIC ACID; NINTEDANIB; OXALIPLATIN; ANTINEOPLASTIC AGENT; INDOLE DERIVATIVE; PLATINUM COMPLEX;

ABDOMINAL PAIN; ADULT; AGED; ALOPECIA; ANEMIA; ARTERIAL THROMBOEMBOLISM; ARTICLE; ASTHENIA; BLEEDING; CANCER COMBINATION CHEMOTHERAPY; CONSTIPATION; CONTINUOUS INFUSION; CONTROLLED STUDY; COUGHING; DECREASED APPETITE; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DIZZINESS; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSGEUSIA; DYSPHONIA; EPISTAXIS; FATIGUE; FEMALE; FEVER; HAND FOOT SYNDROME; HEADACHE; HUMAN; HYPERBILIRUBINEMIA; HYPERTENSION; HYPERTRANSAMINASEMIA; INSOMNIA; INTESTINE OBSTRUCTION; JAUNDICE; LIVER TOXICITY; LUNG EMBOLISM; MACULOPAPULAR RASH; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; METASTATIC COLORECTAL CANCER; MINIMUM PLASMA CONCENTRATION; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROTOXICITY; NEUTROPENIA; OPEN STUDY; PARALLEL DESIGN; PARESTHESIA; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; RASH; RECOMMENDED DRUG DOSE; SKIN MANIFESTATION; THROMBOCYTOPENIA; TOOTH PAIN; UPPER ABDOMINAL PAIN; VENOUS THROMBOEMBOLISM; VOMITING; ADENOCARCINOMA; CANCER STAGING; CLINICAL TRIAL; COLORECTAL NEOPLASMS; COMPARATIVE STUDY; FOLLOW UP; METASTASIS; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; SECONDARY; SURVIVAL RATE; VERY ELDERLY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BEVACIZUMAB; COLORECTAL NEOPLASMS; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; INDOLES; LEUCOVORIN; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; PROGNOSIS; SURVIVAL RATE;

EID: 84943764507     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdv286     Document Type: Article

References (21)

1. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-2342.
2. Strickler JH, Hurwitz HI. Bevacizumab-based therapies in the first-line treatment of metastatic colorectal cancer. Oncologist 2012; 17: 513-524.
3. Capdevila J, Carrato A, Tabernero J, Grande E. What could Nintedanib (BIBF 1120), a triple inhibitor of VEGFR, PDGFR, and FGFR, add to the current treatment options for patients with metastatic colorectal cancer?. Crit Rev Oncol Hematol 2014; 92: 83-106.
4. Casanovas O, Hicklin DJ, Bergers G, Hanahan D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 2005; 8: 299-309.
5. Erber R, Thurnher A, Katsen AD et al. Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms. FASEB J 2004; 18: 338-340.
6. Kopetz S, Hoff PM, Morris JS et al. Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance. J Clin Oncol 2010; 28: 453-459.
7. Hilberg F, Roth GJ, Krssak M et al. BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res 2008; 68:4774-4782.
8. McCormack PL. Nintedanib: first global approval. Drugs 2015; 75: 129-139.
9. Mross K, Buchert M, Frost A et al. Vascular effects, efficacy and safety of nintedanib in patients with advanced, refractory colorectal cancer: a prospective phase I subanalysis. BMC Cancer 2014;14: 510.
10. Saltz LB, Clarke S, Diaz-Rubio E et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008; 26: 2013-2019.
11. Van Cutsem E, Prenen H, Guillen-Ponce C et al. A phase l/lI, open-label, randomised study of BIBF 1120 plus mFOLFOX6 compared to bevacizumab plus mFOLFOX6 in patients with metastatic colorectal cancer. Eur J Cancer 2011; 47:8-9 (Abstract 14LBA).
12. Schmoll HJ, Cunningham D, Sobrero A et al. Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study (HORIZON III). J Clin Oncol 2012; 30: 3588-3595.
13. Fuchs CS, Fakih M, Schwartzberg L et al. TRAIL receptor agonist conatumumab with modified FOLFOX6 plus bevacizumab for first-line treatment of metastatic colorectal cancer: a randomized phase 1b/2 trial. Cancer 2013; 119: 4290-4298.
14. Nishina T, Takano Y, Denda T et al. A phase II clinical study of mFOLFOX6 plus bevacizumab as first-line therapy for Japanese advanced/recurrent colorectal cancer patients. Jpn J Clin Oncol 2013; 43: 1080-1086.
15. Infante JR, Reid TR, Cohn AL et al. Axitinib and/or bevacizumab with modified FOLFOX-6 as first-line therapy for metastatic colorectal cancer: a randomized phase 2 study. Cancer 2013; 119: 2555-2563.
16. Venook AP, Niedzwiecki D, Lenz H et al. CALGB/SWOG 80405: phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (mCRC). J Clin Oncol 2014; 32: Abstr LBA3.
17. Douillard JY, Oliner KS, Siena S et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 2013; 369: 1023-1034.
18. Gopal A, Flores RA, Lacouture ME, Wu S. Differential effects of bevacizumab on the risk of hand-foot syndrome associated with cytotoxic chemotherapy: an updated meta-analysis. J Clin Oncol 2013; 31: Abstr 9622.
19. Eisen T, Shparyk Y, Jones R et al. Phase II efficacy and safety study of nintedanib versus sunitinib in previously untreated renal cell carcinoma (RCC) patients. J Clin Oncol 2013; 31: Abstr 4506.
20. Reck M, Kaiser R, Mellemgaard A et al. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. Lancet Oncol 2014; 15: 143-155.
21. Hanna NH, Kaiser R, Sullivan RN et al. LUME-Lung 2: a multicenter, randomized, double-blind, phase III study of nintedanib plus pemetrexed versus placebo plus pemetrexed in patients with advanced nonsquamous non-small cell lung cancer (NSCLC) after failure of first-line chemotherapy. J Clin Oncol 2013; 31: Abstr 8034.